WS
OVID icon

Wedbush Securities’s Ovid Therapeutics OVID Stock Holding History

Wedbush Securities’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,900
Closed -$63K – 948
2020
Q3 		$63K Buy
+10,900
New +$72.9K 0.01% 862
2020
Q2 		– Sell
-29,090
Closed -$87K – 1001
2020
Q1 		$87K Buy
+29,090
New +$98K 0.01% 787

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities's OVID Position: Q4 2020 in Review

Wedbush Securities sold out of Ovid Therapeutics (OVID) in Q4 2020, closing a stake of 10,900 shares — an estimated $63K sold.

Wedbush Securities first reported a position in OVID in Q1 2020 and held it in 2 quarters. The position peaked at $87K in Q1 2020. 83 funds tracked by Wall St. Rank hold OVID as of Q4 2020.

  • Wedbush Securities reported no remaining Ovid Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 10,900 Ovid Therapeutics shares in Q4 2020, an estimated $63K.
  • Wedbush Securities first reported a position in Ovid Therapeutics in Q1 2020 and held it in 2 quarters.
  • Wedbush Securities's Ovid Therapeutics position peaked at $87K in Q1 2020.
  • 83 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.